Gaucher disease is a genetic metabolic disorder that usually results in bone problems. Shire Pharmaceuticals' Vpriv medication is being approved by FDA for treating the bone complication in patients' with Gaucher disease.
(prHWY.com) August 22, 2012 - Fontana, CA -- August 22, 2012 USA, California (Acedrugstore.com): Shire pharmaceutical has declared that the clinical trial results of its drug Vpriv had shown an increase in the bone density of the spine in patients suffering from Gaucher disease, while the drug Cerezyme with the same function produced by its competitor Sanofi failed to impress FDA.
The news of the FDA approval of its drug Vpriv has come at the right time, as the FDA has recently approved its rival drug against its huge market selling medication for ADHD.
Gaucher disease is usually characterized by organ damage and bone complications and is resulted due to a metabolic enzyme deficiency, which is genetic or hereditary. A nip and tuck affair of the drugs, Vpriv and Cerezyme clinical trial was designed to conclude the effectiveness of both the drugs in treating the Gaucher disease allied bone problem.
The patients consuming Vpriv showed a significant advance in the measurements of bone that was observed after a time span of about 9 months; whereas, patients on Cerezyme treatment failed to show any improvement.
Ari Zimran, a professor of a medical school in Jerusalem claimed that bone abnormalities are the most common symptoms observed by maximum number of patients suffering from type 1 Gaucher disease.
He also added that the results obtained by the study proved that Vpriv is very effective and potent in curing some preferable markers related to bone disease of Gaucher, thereby aiding in achieving the therapeutic target in a quick manner by the patients.
This inborn error of metabolism, Gaucher disease is evaluated to be afflicting around 10,000 individuals worldwide, but investors are of view that these rare-genetic disorder drugs can control its premium prices.
Cerezyme was the only drug available for treating the bone complication in Gaucher patients till the advent of Vpriv. The clinical trial data of Vpriv provide an edge and aids in distinguishing itself from the other treatment options of Gaucher disease in the world.
For more:
http://www.acedrugstore.com/
Acedrugstore.com
4th lane, 278
Stockton, California states, USA
###